Arcellx (NASDAQ:ACLX) Cut to Hold at Needham & Company LLC

Needham & Company LLC lowered shares of Arcellx (NASDAQ:ACLX) from a buy rating to a hold rating in a research report report published on Monday, Marketbeat Ratings reports.

ACLX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 price target on shares of Arcellx in a research note on Wednesday, February 4th. Citigroup restated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Truist Financial reaffirmed a “hold” rating and issued a $120.00 target price (down from $134.00) on shares of Arcellx in a report on Monday. Canaccord Genuity Group reissued a “buy” rating and set a $130.00 price target on shares of Arcellx in a report on Monday, December 8th. Finally, William Blair cut shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research note on Monday. One analyst has rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $111.87.

Arcellx Stock Up 0.0%

Shares of ACLX opened at $113.76 on Monday. Arcellx has a 12 month low of $47.86 and a 12 month high of $114.26. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of -28.95 and a beta of 0.36. The company has a 50-day moving average price of $69.82 and a two-hundred day moving average price of $75.65.

Insider Activity

In other news, insider Christopher Heery sold 7,437 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the sale, the insider directly owned 29,631 shares of the company’s stock, valued at $1,941,126.81. This represents a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 19,450 shares of company stock worth $1,283,477 in the last quarter. 8.35% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcellx

Several large investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock valued at $1,893,000 after acquiring an additional 1,390 shares during the last quarter. Empowered Funds LLC acquired a new position in Arcellx in the first quarter valued at about $1,768,000. Intech Investment Management LLC boosted its holdings in Arcellx by 27.7% during the first quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock worth $1,441,000 after buying an additional 4,760 shares during the last quarter. Teacher Retirement System of Texas grew its position in shares of Arcellx by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock worth $585,000 after buying an additional 151 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Arcellx during the 2nd quarter worth about $563,000. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Key Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for up to $7.8 billion, a transformational M&A outcome that explains much of the upward price pressure by crystallizing acquisition value for ACLX shareholders. Gilead to buy Arcellx
• Neutral Sentiment: HC Wainwright published a FY2030 EPS projection (very bullish numerically) with a $115 price target but maintained a “Neutral” rating — the target is close to the current trade and offers limited additional upside. (Source: market research note)
• Neutral Sentiment: Short‑interest data reported for late February shows 0 shares and a 0.0 days‑to‑cover figure, which appears to be a data anomaly and therefore provides no clear signal about short‑seller pressure.
• Negative Sentiment: A broad set of sell‑side shops (Leerink, Evercore, Needham, Wells Fargo, Citigroup, Truist, Canaccord and others) moved ACLX toward “Hold” from stronger stances (strong‑buy/buy/outperform). Several firms cut or trimmed price targets (Truist cut to $120 from $134; others adjusted targets and ratings), creating short‑term headwinds and mixed sell signals despite the M&A news. Citigroup downgrades Arcellx Analyst coverage roundup

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.